Convergence Pharmaceuticals Limited

Glaxo Group Limited

Robert James Gleave

Paul John Beswick

Emmanuel Hubert Demont

Sadie Vile

Andrew Peter Cridland

Jag Paul Heer

Daryl Simon Walter

Neville Hubert Nicholson

Alister Campbell

Lee William Page

Simon Edward Ward

Shuji Hachisu

David Kenneth Dean

Stefan Senger

David George Hubert Livermore

Nicholas Bertheleme

Laura J Chambers

Andrew Peter Moses

Nicolas Bertheleme

Simon E Ward

Laura Jane Chambers

David John Davies

Iain Patrick Chessell

Mythily Vimal

The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial. Formula (I) wherein A is: (II) or (III)  

Tetrazole compounds as calcium channel blockers

The present invention relates to novel tetrazole compounds of Formula (I) wherein A is (II) or (III); to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial. wherein A is 

The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

3-pyridylcarbonyl-piperazinylsulfonyl derivatives

The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

Piperazine derivatives used as CAV2.2 calcium channel modulators

The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

Receptor antagonists and their methods of use

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: Rrepresents hydrogen, halogen, Calkyl, Carylmethyl-, Calkenyl, Calkynyl or Ccycloalkylmethyl-; and any of said Calkyl, Carylmethyl-, Calkenyl, Calkynyl or Ccycloalkylmethyl- is optionally substituted with 1, 2 or 3 halogen atoms; and Rrepresents hydrogen, fluorine or methyl;or Rand Rtogether with the carbon atoms to which they are attached form a benzene ring optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from the group consisting of Calkyl, Calkenyl and Calkynyl. The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation or neurodegeneration.

Pyrrole and isoindole carboxamide derivatives as P2X7 modulators

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.

Imidazolidine carboxamide derivatives as P2X7 modulators

Growing community of inventors

Harlow, United Kingdom

Robert James Gleave